Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
41.96
Oct 22 • 3:59 PM ET Dollar change+0.99 Percentage change(2.42%)
Aftermarket Close
41.50
Aftermarket • 7:30 PM ET Dollar change-0.46 Percentage change(-1.10%)
Oct 20, 1:03 PMPositive duvakitug Phase 2b data and healthcare rally lift Sanofi ADR 4%
Index
-
Market Cap
100.01B
Enterprise Value
120.12B
Income
4.69B
Sales
53.47B
Book/sh
32.59
Cash/sh
3.05
Employees
76493
IPO
Jul 01, 2002
P/E
21.61
Forward P/E
8.15
PEG
1.37
P/S
1.87
P/B
1.29
P/C
13.78
P/FCF
8.30
EV/EBITDA
5.34
EV/Sales
2.25
Quick Ratio
0.64
Current Ratio
0.99
Debt/Eq
0.34
LT Debt/Eq
0.24
Option/Short
Yes / Yes
EPS (ttm)
1.94
EPS next Y
5.15
EPS next Q
1.56
EPS this Y
3.50%
EPS next Y
6.55%
EPS next 5Y
5.96%
EPS past 3/5Y
-11.86% -15.52%
Sales past 3/5Y
2.90% 3.69%
EPS Y/Y TTM
-30.90%
Sales Y/Y TTM
23.68%
EPS Q/Q
-32.22%
Sales Q/Q
18.71%
Insider Own
0.00%
Insider Trans
-
Inst Own
7.98%
Inst Trans
-0.55%
ROA
3.12%
ROE
5.70%
ROIC
4.80%
Gross Margin
66.29%
Oper. Margin
27.17%
Profit Margin
8.78%
SMA20
3.88%
SMA50
-1.19%
SMA200
-5.69%
Trades
Shs Outstand
2.43B
Shs Float
2.38B
52W High
52.68 -20.35%
52W Low
39.07 7.40%
Volatility
1.82% 1.68%
ATR (14)
0.87
RSI (14)
55.99
Beta
0.29
Rel Volume
1.16
Avg Volume
2.97M
Volume
3,458,568
Perf Week
4.14%
Perf Month
0.72%
Perf Quarter
-3.21%
Perf Half Y
-11.72%
Perf YTD
-13.41%
Perf Year
-16.06%
Perf 3Y
-19.39%
Perf 5Y
-15.50%
Perf 10Y
11.75%
Prev Close
40.97
Price
41.96
Change %
2.42%
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France.
CEO & DirectorMs. Belen Garijo Lopez M.D.
Executive VP & CFOMr. Francois-Xavier Roger
Chief Scientific Officer & Head of ResearchDr. Michael Quigley Ph.D.
Head of Investor Relations & General MedicinesMr. Thomas Kudsk Larsen
Executive VP & General CounselMs. Jamie Haney